Cite
HARVARD Citation
Alberts, D. et al. (2007). Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). International journal of gynecological cancer. 17 (4), pp. 784-788. [Online].